Pfizer‘s groundbreaking work in genetics, blood cancer, vaccines, and strategic M&A set the path not only for future business growth but also for significant advancements in patient care.

Pfizer’s Research and Development Excellence in 2023

Pfizer’s commitment to R&D has been recognised with three awards for their remarkable contributions in genetics, blood cancer, and vaccines for infectious diseases.

The US FDA approval of NGENLA™, a long-acting once-weekly treatment for Pediatric Growth Hormone Deficiency (GHD), marked a significant milestone in the field of genetics. NGENLA™, developed in collaboration with OPKO Health, is designed to alleviate the burden of daily injections for children with GHD, offering a more convenient and potentially adherence-improving treatment regimen. The FDA’s endorsement is grounded in a comprehensive Phase 3 study that demonstrated NGENLA’s non-inferiority to daily somatropin, with a comparable safety profile.

The recognition for R&D in blood cancer was for achieving accelerated approval of ELREXFIO™ (elranatamab-bcmm), a novel immunotherapy for adult patients with relapsed or refractory multiple myeloma (RRMM). ELREXFIO™ is a bispecific antibody that activates T-cells to target and destroy myeloma cells, representing a potential new standard of care for patients who have exhausted other treatment options. The FDA’s accelerated approval was based on the promising results of the Phase 2 MagnetisMM-3 trial, which showed significant responses in a highly refractory patient population. The therapy’s subcutaneous delivery and reduced dosing frequency after 24 weeks could enhance patient quality of life and long-term treatment tolerability.

In the vaccines category, Pfizer’s PENBRAYA™ received approval as the first and only vaccine to prevent the five most common serogroups causing meningococcal disease in adolescents. This pentavalent vaccine simplifies the vaccination process, potentially increasing coverage and protection against invasive meningococcal disease (IMD). The FDA’s decision was supported by robust Phase 2 and Phase 3 trial data, demonstrating the vaccine’s safety, tolerability, and immunogenicity.

M&A: Acquisition of Seagen

Pfizer’s strategic acquisition of Seagen earned them the M&A award, reflecting the company’s foresight and commitment to expanding its oncology portfolio. The $43bn transaction brings Seagen’s proprietary antibody-drug conjugate (ADC) technology into Pfizer’s fold, enhancing its ability to develop and commercialise transformative cancer medicines. Seagen’s four in-line medicines, along with its robust pipeline, significantly bolster Pfizer’s oncology offerings and promise to drive growth and innovation in cancer treatment.

Pfizer’s integration of Seagen’s ADC technology is expected to unlock novel combinations and next-generation biologics, doubling the size of Pfizer’s oncology pipeline. The acquisition aligns with Pfizer’s mission to improve and extend the lives of cancer patients, as they now possess more than 25 approved medicines and biosimilars across more than 40 indications.

Company Profile

Headquartered in the US, Pfizer is a global pharmaceutical corporation with a rich history of over 170 years. As a research-intensive company, Pfizer has consistently been at the forefront of developing innovative therapies and vaccines that address a wide range of diseases and conditions. With its recent accolades and strategic acquisitions, Pfizer continues to solidify its position as a leader in the pharmaceutical industry, dedicated to delivering breakthroughs that change patients’ lives.

Contact details:

66 Hudson Boulevard East

New York, NY 10001-2192